

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Cycloserine

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Cycloserine capsules	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Cycloserine may be approved if the following criteria are met:

- I. Individual has a diagnosis of pulmonary or extrapulmonary tuberculosis; **AND**
- II. The causative organisms are susceptible to cycloserine; **AND**
- III. Primary medications (such as, isoniazid, rifampin, pyrazinamide, ethambutol) have proven inadequate or cannot be used due to resistance of the causative organism (ATS/CDC/IDSA 2016; WHO 2019); **AND**
- IV. Cycloserine will be administered in conjunction with other effective agents and not as the sole therapeutic agent;

OR

- V. Individual has a diagnosis of acute urinary tract infection; **AND**
- VI. The causative organisms are susceptible to cycloserine; **AND**
- VII. Conventional therapy for causative organism has failed.

Cycloserine may not be approved for the following criteria:

- I. Individual has epilepsy; **OR**
- II. Individual has depression, severe anxiety, or psychosis; **OR**
- III. Individual has severe renal insufficiency; **OR**
- IV. Individual has excessive concurrent use of alcohol.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 4, 2019.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
4. Nahid P, Dorman SE, Alipanah N, et. al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. *Clin Infect Dis*. 2016;63(7):853–6.
5. Schluger NW, Heysell SK, Friedland G. Treatment of drug-resistant pulmonary tuberculosis in adults. Last updated: September 18, 2019. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: October 7, 2019.
6. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019. Available at: <https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf?ua=1>. Accessed: October 6, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.